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Animal studies show that increasing large bowel butyrate concen-
tration through ingestion of butyrylated or resistant starches op-
poses carcinogen-induced tumorigenesis, which is consistent with
population data linking greater ﬁber consumption with lowered
colorectal cancer (CRC) risk.Butyrate has been shown to regulate
the apoptotic response to DNA damage. This study examined the
impact of increasing large bowel butyrate concentration by di-
etary butyrylated starch on the colonic epithelium of rats treated
with the genotoxic carcinogen azoxymethane (AOM). Four groups
of 10 male rats were fed AIN-93G based-diets containing either
low amylose maize starch (LAMS), LAMS with 3% tributyrin,
10% high amylose maize starch (HAMS) or 10% butyrylated
HAMS (HAMSB). HAMS and HAMSB starches were cooked
by heating in water. After 4 weeks, rats were injected once with
AOM and killed 6 h later. Rates of apoptosis and proliferation
were measured in colonic epithelium. Short-chain fatty acid con-
centrations in large bowel digesta and hepatic portal venous
plasma were higher in HAMSB than all other groups. Apoptotic
rates in the distal colon were increased by HAMSB and correlated
with luminal butyrate concentrations but cellular proliferation
rates were unaffected by diet. The increase in apoptosis was most
marked in the base and proliferative zone of the crypt. Regulation
of luminal butyrate using HAMSB increases the rates of apoptotic
deletion of DNA-damaged colonocytes. We propose this pro-
apoptotic function of butyrate plays a major role reducing
tumour formation in the AOM-treated rat and that these data
support a potential protective role of butyrate in CRC.
Introduction
Colorectal cancer (CRC) is a major cause of death and its incidence is
increasing throughout the world (1). The majority of case-controlled
epidemiological studies have shown a dose-dependent protective ef-
fect against CRC of diets high in ﬁber, although prospective studies
have shown less effect (see (2)). These apparent inconsistencies may
reﬂect the different quantities and relative contributions of the major
components of the predominant dietary ﬁber sources consumed in the
various studies. Based on early deﬁnitions of dietary ﬁber (3), it was
thought that non-starch polysaccharides (NSPs) were the most impor-
tant contributors to the health beneﬁts of ﬁber while the contribution
of resistant starch (RS) was discounted. RS is that fraction of ingested
starch that escapes small intestinal digestion and enters the human
large bowel and it is now recognized as a dietary ﬁber component (4).
Population studies have identiﬁed RS consumption as protective
against CRC (5) and it appears that populations at low risk of CRC
consume relatively little NSP but have high intakes of RS (6). In the
large bowel, RS together with a fraction of NSP that varies by source
undergoes bacterial fermentation with the production of short-chain
fatty acids (SCFAs), mainly acetate, propionate and butyrate (7). Bu-
tyrate may protect against oncogenesis as it enhances apoptosis of
genetically damaged cells, inhibits cell proliferation and promotes
differentiation in CRC cells in vitro (7–10).
Apoptosis provides a system for the removal of aged or damaged
cells through programmed autolysis. Though ﬁrst recognized for its
role in early development and morphogenesis (11,12) apoptosis also
provides a defence against tumorigenesis. Genotoxin-induced cellular
anomalies such as DNA double-strand breaks, inappropriate poly-
ploidy, telomere dysfunction and abnormal mitoses can all induce
apoptosis (13). Rates of apoptosis are usually low in the colon (14);
disruption of this protective process is often involved with tumour
initiation and development (15,16).
Increasing large bowel digesta butyrate concentration by the inges-
tion of RS increases rates of apoptosis in distal colonic epithelium
(17,18), as well as reducing large bowel tumour number and incidence
in carcinogen-treated rats (19–21). Although fermentation of RS by the
microﬂora can elevate butyrate levels in the large bowel, there may be
limitations to the effectiveness of RS as the SCFA proﬁle produced can
vary withthe source(22). Acylatedstarcheshave beenshownto deliver
speciﬁcSCFAtothelargebowelandingestionofbutyrylatedstarchhas
been shown to deliver butyrate to the colon in animals (23,24) and
humans (25,26). Butyrylated high amylose maize starch (HAMSB)
has been shown to reduce the incidence and number of tumours in
carcinogen-treated rats (27) and to protect from diet-induced genomic
damage to colonic epithelium (28).
The aim of this study was to investigate the effects of increasing
large bowel butyrate concentration by dietary butyrylated starch on
the colonic epithelium of rats treated with the genotoxic carcinogen
azoxymethane (AOM). The study examined the effects of RS and
butyrylated-RS on the acute apoptotic and proliferative cellular re-
sponses of the colonic epithelium to exposure to the pro-carcinogen
AOM, which causes the methylation of guanine to the adduct O6-
methylguanine in colonocytes of rats. To differentiate between the
effects of butyrate delivered to the colon directly (as opposed to
systemically through small intestinal absorption), a group of rats were
fed a low amylose maize starch diet with added tributyrin (LAMST).
In addition, changes in the colonic luminal environment relevant to
CRC risk were examined.
Materials and methods
Animals and diets
Forty male Sprague–Dawley rats of 4 weeks of age were purchased from the
Animal Resource Centre, Murdoch University, Western Australia. The animals
were housed in wire-bottomed cages in a temperature-controlled room (23 ±
1C) with a 12 h light/dark cycle. After 2 weeks acclimatization, the rats were
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weights (215 ± 2 g).
The animals were given free access to food and water throughout the study
and were fed 1 of 4 experimental diets. These diets have been described pre-
viously (27) and were based on a balanced modiﬁcation of the AIN-93G diet
(29). Brieﬂy, they contained 530g low RS maize starch (low amylose maize
starch, LAMS), 200g casein, 70g sunﬂower seed oil and 50g a-cellulose/kg of
diet. Choline, methionine, minerals, vitamins and a permitted anti-oxidant
were added as described previously (24). The amount of LAMS starch in the
diet was reduced to allow for the addition of high amylose maize starch
(HAMS), HAMSB and tributyrin (Sigma Chemical Co., St Louis, MO). The
experimental diets were control (LAMS, low RS), low amylose maize starch
with 3% tributyrin (LAMST, low RS), 10% HAMS (high RS) and 10%
HAMSB (high RS). The latter was manufactured by National Starch Food
Innovation (Bridgewater, New Jersey) and had a degree of substitution of
0.25 [i.e. 0.25 of the hydroxyl groups on each starch D-glucopyranosyl unit
were derivatized or replaced by the substituent acid (30)]. HAMS and HAMSB
were heated with water and spray dried to minimize retrogradation and crystal
formation (31). They were added to the diets to mimic the condition of starches
consumed in foods by humans as cooking decreases resistance to amylolysis
(24). All dietswere preparedweekly at CSIRO and stored at 4C. The rats were
fed fresh diet daily.
After 28 days of feeding the experimental diets, rats were injected with 15 mg
of AOM/kg subcutaneously (Sigma Chemical Co.). Six hours later the animals
were anaesthetized with halothane and blood collected from the hepatic portal
veinand abdominalaorta.The colon wasexcised,ﬂushedwithchilled saline,the
distal and proximal 0.5 cm discarded and 2cm sections taken from both the
proximal and the distal ends. The tissues were ﬁxed in 10% buffered formalin
for 20 h, then washed and stored in 70% alcohol before being embedded in
parafﬁn. The caecum was removed, weighed and samples of caecal, proximal
colonic and distal colonic digesta were collected for pH measures. Digesta
samples were mixed with 3 volumes of internal standard (heptanoic acid, 1.68
mmol/l) and stored at  20 C for SCFA analysis.
All procedures involving animals were approved by the Commonwealth
Scientiﬁc and Industrial Research Organisation (CSIRO) Human Nutrition
Animal Ethics Committee and complied with the NHMRC Australian Code
of Practice for the Care and Use of Animals for Scientiﬁc Purposes 7th ed (32).
All slides assessed for rates of colonic epithelial apoptosis and proliferation
were randomly encoded and examined by an independent observer unaware of
the dietary treatments.
Short-chain fatty acids
Digesta homogenate samples were processed for SCFA analysis using gas
chromatography (GC) as described previously (24). Plasma SCFA were
extracted for GC analysis using diethyl ether as described previously (33).
Apoptosis measurement
Cross sections of 4lm thickness were cut for all histological techniques. Rates
of apoptosis were determined using morphological assessment (34) of the
distal and proximal colon. The rate of apoptosis was also measured in the
distal colon using immunohistochemical staining and quantiﬁcation of cas-
pase-3 to enable comparison with the determination by morphological assess-
ment. For the morphological assessment, tissue sections from the distal and
proximal colon were rehydrated through xylene and ethanol, stained with
Harris’s hematoxylin (BDH Laboratory Supplies, England) and evaluated un-
der a light microscope (BX41, Olympus, Tokyo, Japan). Twenty intact crypts
were used for apoptotic cell identiﬁcation per animal. Cell shrinkage, presence
of condensed chromatin, and sharply delineated cell borders surrounded by
a clear halo (34) were used as deﬁning variables for morphological assessment.
The number of apoptotic cells in each crypt, the length of the crypt (in cells)
and the position of the apoptotic cells within the crypt where position one was
at the base were recorded. The apoptotic index was calculated as the mean
number of apoptotic cells per crypt column divided by the total number of cells
in the column multiplied by 100.
Rates of apoptosis were also quantiﬁed using an immunohistochemical
staining technique that was a modiﬁed version of the method of Marshmann
et al. (35). The method used rabbit monoclonal Asp175 caspase-3 primary
antibody (Cell Signalling Technology, Beverley, MA) to detect the large
(p17) fragment of activated caspase-3; this antibody does not recognize pro-
caspase-3 or other caspases. Following deparafﬁnisation and rehydration, an-
tigen retrieval was performed in 10 mM sodium citrate/TBST buffer pH 6.0 at
95C for 20 min. Slides were cooled, washed in TBS and immersed in 3%
H2O2 for 10 min to block endogenous peroxidase activity. Powervisionþ pre-
antibody blocking solution (Immunovision Technologies, Brisbane, CA) was
used for 20 min, followed by incubation with anticleaved caspase-3 diluted
1:200 in blocking solution overnight at 4C. Next morning, sections were
washed and incubated for 20 min in post-antibody blocking solution (Immu-
novision Technologies) before addition of Poly-HRP anti-mouse/rabbit IgG 2
antibody(ImmunovisionTechnologies)for30 min. Sectionswere developedin
3,3#-diaminobenzidine(DAB)for10 minand counterstained withhematoxylin
for 1 min before dehydration and mounting. Twenty intact crypts per animal
were scored for caspase-3 and the number of cells per crypt column recorded.
The apoptotic index was calculated as the mean number of caspase-3 stained
cells per crypt column divided by the total number of cells in the column
multiplied by 100. Sections were visualized on an Olympus BX41 light mi-
croscope equipped with a Diagnostic Instruments Spot RT camera. Images
were taken and assessed using the Image Pro Plus v.4.0.1 software package
(media Cybernetics, Silver Spring, MD).
Cell proliferation
Distal colonic epithelial proliferation was measured using immunohistochem-
ical staining with Ki67 monoclonal antibody (DAKO, Glostrup, Denmark).
Brieﬂy, sections of the distal colon were placed in xylene and rehydrated in
a graded series of ethanol. Antigen retrieval was performed in a 95C water
bath with 0.1 M citrate buffer for 25 min. Endogenous peroxidase activity was
blocked by immersing the slides in 0.3% H2O2 in methanol for 20 min. Slides
were incubated in 5% goat serum to block non-speciﬁc binding before Ki67
antibody was applied 1:500 in blocking solution for 1 h at room temperature.
Following washing and HRP anti-mouse IgG secondary antibody application
(DAKO), the antigen–antibody complex was made visible by incubation with
DAB before counterstaining with hematoxylin for 1 min. Twenty intact crypts
per animal were chosen for analysis and scored for presence of Ki67 staining
and the number of cells per crypt column recorded. The proliferative index was
calculated as the mean number of Ki67 stained cells per crypt column divided
by the total number of cells in the column multiplied by 100.
Statistical analyses
Analyses were performed using GraphPad Prism Version 4.00 (GraphPad
Software Inc. San Diego, CA). Data are expressed as mean ± standard error
of the mean. The apoptotic indices derived from morphological assessment
were transformed using y 5 log y before a signiﬁcance test was performed.
One-way analysis of variance with Tukey post hoc tests were used to compare
data between treatment groups and differences were considered signiﬁcant
when P , 0.05. The correlations involving distal colonic apoptotic index de-
rived from morphological assessment were analyzed using Spearman’s correla-
tiontestsasthese datawerenon-parametricallydistributed.Pearson’s correlation
tests were used to analyse correlations between other parametrically distributed
variables.
Results
Animal and digesta measurements
There were no signiﬁcant differences in the ﬁnal body weights or
digesta weights in the proximal and distal colon (Table I). Rats fed
HAMSB had higher caecal tissue and digestaweights (P , 0.001) and
lower pH (P , 0.001) in the large bowel compared with rats fed
LAMS, LAMST and HAMS. The large bowel digesta pH values of
rats fed HAMS were lower than those of rats fed LAMST (P , 0.01).
Table I. Final measures of rats fed diets for 28 days containing LAMS,
LAMS with 3% tributyrin (LAMST), HAMS and HAMSB
LAMS LAMST HAMS HAMSB
Body weight(g) 383 ± 11 385 ± 9 382 ± 9 378 ± 6
Caecal tissue
weight (g)
0.66 ± 0.03a 0.64 ± 0.03a 0.78 ± 0.02a 1.11 ± 0.08b
Digesta weight (g)
Caecum (g) 1.24 ± 0.10a 1.30 ± 0.08a 1.48 ± 0.16a 2.43 ± 0.31b
Proximal colon (g) 0.22 ± 0.07 0.13 ± 0.04 0.39 ± 0.12 0.37 ± 0.09
Distal colon (g) 0.55 ± 0.10 0.39 ± 0.06 0.48 ± 0.08 0.74 ± 0.14
Digesta pH
Caecum 7.19 ± 0.07ac 7.37 ± 0.07a 7.00 ± 0.06c 6.45 ± 0.10b
Proximal colon 7.28 ± 0.08ac 7.30 ± 0.05a 6.94 ± 0.09c 6.57 ± 0.06b
Distal colon 6.93 ± 0.07ac 7.03 ± 0.06a 6.74 ± 0.06c 6.38 ± 0.04b
Values are mean ± standard error of the mean (n 5 9–10). Means with
a different superscript within each row are signiﬁcantly different (P , 0.05).
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The apoptotic index (as measured by morphological assessment of
distal colonic epithelium) was higher in rats fed HAMSB compared
with rats fed LAMS (P , 0.05) and HAMS (P , 0.01, Figure 1A)
whereas no differencewas observed in the proximal colon (Figure 1C).
Apoptoticindiceswerehigherinthedistalthanintheproximalcolonin
all groups (P , 0.001). HAMSB increased the rate of apoptosis com-
pared with LAMS in cells in the distal colon in cellular positions 7–12,
14–15 and 17; compared with LAMST in cellular positions 11–12 and
compared with HAMS in cellular positions 1–2, 11–12, 14–15 and 17
(Figure 2).
Rats fed HAMSB showed signiﬁcantly higher active caspase-3 in
the distal colon crypts compared with those fed HAMS (P , 0.05,
Figure 1B). The distribution of the increase in active caspase-3 stain-
ing was similar in cellular position to that described for apoptosis
measured by morphological assessment (data not shown).
The Ki67 labelling indexin the distal colon was not affected by diet
(Figure 3).
Digesta and plasma SCFA concentrations
The effects of diet on caecal digesta SCFA concentrations are shown in
TableII.Propionate(P, 0.05)andbutyrateconcentrations(P, 0.001)
were signiﬁcantly higher in rats fed HAMSB compared with all other
diets. Total caecal digesta SCFA concentrations were also higher for
rats fed HAMSB compared with those fed LAMST (P , 0.05).
Rats fed HAMSB had higher propionate concentrations in their
proximal colons compared with those consuming LAMST (P ,
0.001) and LAMS (P , 0.05). Proximal butyrate concentrations were
elevated in HAMSB fed rats compared with LAMST (P , 0.001),
LAMS and HAMS (P , 0.01). Total SCFA concentrations were high-
er in rats fed HAMSB than LAMST (P , 0.05).
Distal colonic propionate concentrations were higher in rats fed
HAMSB compared with those of LAMS, LAMST (both P , 0.001)
and HAMS (P , 0.05). HAMSB more than doubled the distal colon
digesta butyrate concentrations compared with all other dietary treat-
ments (P , 0.001). Total SCFA concentrations were higher for rats
fed HAMSB than LAMST (P , 0.01).
Ingestion of HAMSB increased hepatic portal venous propionate
concentrations compared with HAMS and LAMS (P , 0.01) and
LAMST (P , 0.001). It also increased butyrate concentrations com-
pared with HAMS and LAMS (P , 0.01). The hepatic portal butyrate
levels of LAMST rats were intermediate between HAMSB, and
LAMS and HAMS.
Correlations between large bowel variables and epithelial response
Distal colon apoptotic index as measured by morphological assess-
ment was positively correlated with distal colonic propionate and
butyrate concentrations (r 5 0.34, P , 0.05; r 5 0.41, P , 0.02,
respectively) and distal colonic butyrate pools (r 5 0.36, P , 0.05)
and caecal acetate pool (r 5 0.32, P , 0.05). Therewas no correlation
between SCFA concentrations and cellular proliferation.
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Fig. 1. Apoptotic index of the colonic epithelium of rats fed LAMS, LAMS
with 3% tributyrin (LAMST), HAMS and HAMSB 6 h after AOM injection
as determined by (A) morphological assessment of the distal colon,
(B) caspase-3 immunohistochemistry of distal colon and (C) morphological
assessment of the proximal colon. Data are mean ± standard error of the
mean (n 5 9–10). Means with a different superscript are signiﬁcantly
different (P , 0.05).
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Fig. 2. Crypt cell position of AOM-induced apoptosis measured by
morphological assessment of distal colonic epithelium. Data are mean ±
standard error of the mean (n 5 10). aLAMS signiﬁcantly different to
HAMSB; bLAMST signiﬁcantly different to HAMSB; cHAMS signiﬁcantly
different to HAMSB (P , 0.05).
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Fig. 3. (A) Cell proliferation rates in the distal colon as measured by Ki67
immunohistochemistry 6 h after AOM injection in rats fed diets containing
LAMS, LAMS with tributyrin (LAMST), HAMS and HAMSB. Data are
mean ± standard error of the mean (n 5 10). Means with a different
superscript are signiﬁcantly different (P , 0.05).
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This trial showed that increased large bowel digesta butyrate through
the feeding of HAMSB induced higher rates of apoptotic deletion of
cells following acute exposure to a genotoxic agent in rats. In the
gastrointestinal tract, apoptosis is an important protective process
eliminating cells with DNA damage that may otherwise progress to
malignancy. Enhancing rates of apoptosis may be one of the mecha-
nisms by which butyrate protects against cancer induction (36,37).
This SCFA has been shown to promote apoptosis in genetically dam-
aged cells (8) through involvement in both the extrinsic pathway
activated via death receptors and intrinsic apoptotic pathways involv-
ing mitochondria and the release of caspase-activating proteins (38).
Butyrate also promotes apoptosis by regulating gene expression, par-
ticularly those inhibiting histone deacetylase (HDAC) (39).
The ability of butyrate to cause apoptosis in cancer cells may be
linked with speciﬁc tumour suppressors that are silenced during the
oncogenic process. These include GPR109A, a receptor in the lumen-
facing apical membrane of colonic epithelial cells that binds butyrate
with low afﬁnity. The expression of GPR109A is silenced in colon
cancer by DNA methylation whereas its re-expression by butyrate
exposure in cancer cells results in apoptosis without the involvement
of HDAC (40). GPR109A and butyrate also block NF-jB activation
(40,41) which is a pathway also linked to inﬂammatory diseases of the
bowel (42). SLC5A8 (SMCT1) is another transporter that actively
moves butyrate from the colonic lumen into epithelial cells leading
to HDAC inhibition and subsequent tumour suppression. SMCT1 is
expressed in normal colonocytes but is silenced when the cells are
transformed (41). Re-expression of SMCT1 in the presence of buty-
rate results in cellular apoptosis (43). These studies suggest that bu-
tyrate plays an important role in regulating apoptosis using both extra
and intracellular mechanisms.
In the colon stem, cells proliferate at the base of the crypt producing
both pluripotent stem cells and daughter cells; the latter divide for up
to six generations as they migrate up the crypt column (44). The
present study demonstrated that increased digesta butyrate promoted
apoptosis in the base and mid sections of the colonic crypts. These
sections represent the stem cell and proliferative functional zones, and
the data suggest butyrate may promote the deletion of damaged stem
cells and daughter cells. Deletion of damaged stems cells by butyrate
delivered by acylated starch could explain the reduced incidence and
number of colonic tumours in rats fed butyrylated starch (27).
Ingestion of cooked HAMS did not increase rates of apoptosis in
the distal colon of rats in this study and reduced the incidence but not
numbers of tumours in AOM-treated rats in a previous experiment
(27). Despite the different experimental protocols, the digesta and
hepatic portal butyrate concentrations in the two groups of HAMS
rats were similar butsubstantially lower than those inthe HAMSB-fed
rats. This suggests that there may be mechanisms of cancer protection
associated with RS fermentation other than the effects of butyrate and
couldinclude reduced digesta pH andincreased digesta bulkingwhich
may minimize exposure to procarcinogens and minimize damage or
activate repair (45).
In this study, HAMSB was effective at increasing butyrate concen-
tration throughout the entire large bowel, including the distal colon,
which was associated with higher rates of apoptosis. Based on pre-
vious data, it had been expected that the dietary intervention with
HAMS would also lead to higher digesta butyrate and increased rates
of apoptosis (46). This did not occur in this study in which the high RS
starches were cooked and was most likely due to the subsequent
partial gelatinisation of the starches that would reduce the RS content
of HAMS (47). In contrast, the RS content of HAMSB is more stable
on heating and the esteriﬁed butyrate is retained (24) which is re-
ﬂected in the higher butyrate concentrations in all sections of the large
bowel of rats fed cooked HAMSB relative to cooked HAMS.
Tumours occur more frequently in the distal large bowel in the rat
AOM model (48), which is also the primary gastrointestinal cancer
site in humans in the developed world (49). Increasing the supply of
butyrate and hence optimizing the rate of apoptosis in the distal colon
may have public health beneﬁts. Rates of cellular proliferation in the
distal colon were not affected by increased digesta butyrate, an ex-
perimental ﬁnding that may be important in the context of predicting
human CRC risk. It has been suggested that greater ﬁber fermentation
could lead to crypt hyperproliferation and increased risk of carcino-
genesis (50). This suggestion was supported by the ﬁnding that fer-
mentable ﬁber carbohydrate stimulated cell proliferation in the
Apc(Min/þ) mouse model of intestinal cancer in association with
enhanced polyp development (51). However, this effect was seen
largely in the small intestine that is neither the site of CRC nor ﬁber
fermentation in the human intestine. The current data together with
previous studies from this laboratory (e.g. (52)) suggest that greater
SCFA availability in the large bowel acts to promote colonocyte
genetic stability.
The hepatic portal venous butyrate concentration was intermediate
in rats fed LAMST and large bowel digesta butyrate concentrations
were signiﬁcantly lower than in rats fed HAMSB diet. The rate of
distal colonic apoptosis was intermediate in the LAMST animals
suggesting that tributyrin may have had some protective effect on
the colonic epithelium. Oral tributyrin (glycerol tributyrate) is ab-
sorbed in the small intestine and at high doses increases free butyrate
concentration in peripheral plasma for up to 4 h. However, the hepatic
uptake of intestinal butyrate is known to be almost complete (53),
suggesting that systemic delivery of butyrate to the colon would be
limited.
To our knowledge, this is the ﬁrst study to compare the measure-
ment of apoptosis by caspase-3 activation and morphological assess-
ment in the colonic epithelium of rats treated acutely with AOM.
Caspase-3 activation was up-regulated by butyrylated starch, however
the increase was not as large as that seen with morphological assess-
ment. The effector caspases (caspases 3, 6 and 7), responsible for in-
trinsic mitochondrial apoptotic pathways are thought to cause all the
morphological apoptotic features assessed using the hematoxylin stain-
ingmethod(15).Caspase-3immunostaininghasbeenconsideredasuit-
able alternative for apoptotic quantiﬁcation in other models (35), but
the present study suggests other caspases also need to be considered
when quantifying colonic epithelial apoptosis in this model.
In conclusion, we have demonstrated that elevated luminal butyrate
as delivered by HAMSB increased the rate of apoptosis but not colo-
nocyte proliferation in the distal colon of rats in acute response to
Table II. Digesta (lmol/g) and hepatic portal (lM) SCFA concentrations of
rats fed diets containing LAMS, LAMS with 3% tributyrin (LAMST),
HAMS and HAMSB
LAMS LAMST HAMS HAMSB
Caecum
Acetate 56.0 ± 3.3 44.6 ± 5.9 51.1 ± 4.4 47.3 ± 5.7
Propionate 16.8 ± 0.9a 15.5 ± 1.8a 19.4 ± 2.0a 28.2 ± 3.1b
Butyrate 14.0 ± 1.3a 11.0 ± 1.4a 13.3 ± 1.4a 32.1 ± 3.7b
Total 91.1 ± 5.1ab 75.6 ± 9.3a 88.2 ± 7.3ab 111.0 ± 11.5b
Proximal colon
Acetate 48.2 ± 3.2 29.5 ± 4.3 41.8 ± 5.0 39.3 ± 5.7
Propionate 12.9 ± 0.7a 9.1 ± 1.3a 16.2 ± 2.0ab 22.3 ± 2.7b
Butyrate 12.5 ± 1.8a 7.3 ± 2.1a 11.9 ± 2.1a 28.4 ± 5.0b
Total 77.2 ± 5.3ab 48.6 ± 7.7a 73.8 ± 8.8ab 93.1 ± 13.0b
Distal colon
Acetate 46.6 ± 5.1 31.2 ± 4.6 43.2 ± 4.0 38.1 ± 3
Propionate 9.8 ± 1.5ab 8.6 ± 1.5b 15.4 ± 1.8a 24.1 ± 2.0c
Butyrate 12.4 ± 2.2a 9.3 ± 2.1a 12.0 ± 2.2a 29.8 ± 3.0b
Total 71.6 ± 8.8a 2.2 ± 8.4a 74.6 ± 7.2ab 95.4 ± 8.0b
Hepatic portal
venous plasma
Acetate 631 ± 60 466 ± 49 558 ± 39 681 ± 75
Propionate 123 ± 33a 59 ± 8a 107 ± 10a 251 ± 38b
Butyrate 50 ± 9a 102 ± 27ab 51 ± 8a 201 ± 47b
Values are mean ± standard error of the mean (n 5 9–10, except proximal
colon n 5 6–8). Means with a different superscript within each row are
signiﬁcantly different (P , 0.05).
J.M.Clarke et al.
200AOM-induced genotoxicity. This effect provides further evidence
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